Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor

Cancer Research

Volumn 66, Issue 1, 2006, Pages 24-28

  Gattenlöhner, Stefan ^a   Marx, Alexander ^a   Markfort, Birgit ^b   Pscherer, Sibylle ^b   Landmeier, Silke ^b   Juergens, Heribert ^b   Müller Hermelink, Hans Konrad ^a   Matthews, Ian ^c   Beeson, David ^c   Vincent, Angela ^c   Rossig, Claudia ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHIMERIC ANTIBODY; CHIMERIC RECEPTOR; CHOLINERGIC RECEPTOR; CISPLATIN; CYTOKINE; DOXORUBICIN; ETOPOSIDE; FETAL ACETYLCHOLINE RECEPTOR; FETAL ACETYLCHOLINE RECEPTOR ANTIBODY T LYMPHOCYTE RECEPTOR GAMMA CHAIN FUSION PROTEIN; GAMMA INTERFERON; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIGEN BINDING; ANTIGEN BINDING DOMAIN; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; FEMALE; GENE IDENTIFICATION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; RHABDOMYOSARCOMA; SURVIVAL RATE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

AUTOANTIBODIES; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CHOLINERGIC; RECOMBINANT FUSION PROTEINS; RHABDOMYOSARCOMA; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 31544442669     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0542     Document Type: Article

References (21)

1. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78-84.
2. Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ, Wharam MD, Meyer WH. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. J Clin Oncol 2004;22:1398-403.
3. Rooney CM, Smith CA Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferatioa Lancet 1995;345:9-13.
4. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4.
5. Dagher R, Long LM, Read EJ, et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 2002;38:158-64.
6. Tanzarella S, Lionello I, Valentinis B, Russo V, Lollini PL, Traversari C. Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies. Cancer Immunol Immunother 2004;53:519-24.
7. Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther 2004;10:5-18.
8. Gattenloehner S, Vincent A, Leuschner I, et al. The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors. Am J Pathol 1998;152:437-44.
9. Beeson D, Vincent A, Morris A, et al. cDNA and genomic clones encoding the human muscle acetylcholine receptor. Ann N Y Acad Sci 1993;681:165-7.
10. Gattenlohner S, Schneider C, Thamer C, et al. Expression of foetal type acetylcholine receptor is restricted to type 1 muscle fibres in human neuromuscular disorders. Brain 2002;125:1309-19.
11. Matthews I, Sims G, Ledwidge S, et al. Antibodies to acetylcholine receptor in parous women with myasthenia: evidence for immunization by fetal antigen. Lab Invest 2002;82:1407-17.
12. Whiting PJ, Vincent A, Schluep M, Newsom-Davis J. Monoclonal antibodies that distinguish between normal and denervated human acetylcholine receptor. J Neuroimmunol 1986;11:223-35.
13. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A 1995:92:6733-7.
14. Rischer M, Pscherer S, Duwe S, Vormoor J, Jurgens H, Rossig C. Human γδ T cells as mediators of chimeric-receptor redirected anti-tumour immunity. Br J Haematol 2004;126:583-92.
15. Rossig C, Bollard CM, Nuchtern JG, Merchant DA, Brenner MK. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 2001;94:228-36.
16. Schuck A, Mattke AC, Schmidt B, et al. Group II rhabdomyosarcoma and rhabdomyosarcoma-like tumors: is radiotherapy necessary? J Clin Oncol 2004;22:143-9.
17. Kirchner T, Geuder KI, Marx A, Muller-Hermelink HK. [Nicotinic acetylcholine receptors in tumors with rhabdomyomatous differentiation. Immunohistochemical and molecular genetic demonstration]. Verh Dtsch Ges Pathol 1990;74:409-14.
18. Vincent A, Newland C, Brueton L, et al. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 1995;346:24-5.
19. Onda M, Wang QC, Guo HF, Cheung NK, Pastan I. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res 2004;64: 1419-24.
20. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994;15:42-52.
21. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy- resistant hairy-cell leukemia. N Engl J Med 2001;345:241-7.